aTyr Pharma
ATYR
50 hedge funds and large institutions have $55.8M invested in aTyr Pharma in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 8 closing their positions.
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
0% more funds holding
Funds holding: 50 → 50 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
61% less capital invested
Capital invested by funds: $143M → $55.8M (-$86.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Gruss Capital Management
New York
|
+$3.26M |
| 2 |
RIM
RS Investment Management
San Francisco,
California
|
+$2.03M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.03M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$987K |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$271K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.88M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.52M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$1.07M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$1.07M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$730K |
ATYR Hedge Fund Activity: Q1 2016 in Review
50 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q1 2016, worth a combined $55.8M — down 61% from $143M a quarter earlier.
Fund positioning in ATYR was balanced in Q1 2016: 8 funds opened new positions, 8 closed out, 17 added to existing stakes and 16 trimmed.
The largest buyer was Gruss Capital Management, opening a new position worth an estimated $3.26M. The largest seller was EcoR1 Capital, cutting an estimated $3.88M.
- 50 institutional investors held aTyr Pharma (ATYR) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $55.8M of aTyr Pharma stock for Q1 2016, down 61% quarter-over-quarter.
- 8 funds opened new aTyr Pharma positions in Q1 2016 and 8 closed out, a net change of 0 holders.
- The largest aTyr Pharma buyer in Q1 2016 was Gruss Capital Management, an estimated $3.26M added.
- The largest aTyr Pharma seller in Q1 2016 was EcoR1 Capital, an estimated $3.88M sold.
Based on aggregated 13F filings for Q1 2016.